Format

Send to

Choose Destination
J Nucl Med. 2017 Aug;58(8):1196-1200. doi: 10.2967/jnumed.117.191023. Epub 2017 Jun 29.

177Lu-PSMA Radioligand Therapy for Prostate Cancer.

Author information

1
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California wfendler@mednet.ucla.edu.
2
Department of Nuclear Medicine, Ludwig Maximilians University of Munich, Munich, Germany.
3
Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany.
4
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California.
5
Department of Nuclear Medicine, Medical Faculty, University Hospital Essen, Essen, Germany.
6
Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany; and.
7
Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Erratum in

Abstract

177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. The current literature suggests that this therapy is well tolerated and effective. On the basis of clinical need and current evidence, the therapy is being implemented in a growing number of centers worldwide. Here, we review important aspects of 177Lu-PSMA RLT, including patient stratification, the therapy protocol, concomitant medication, and follow-up, to inform medical staff involved in the RLT and care of patients with metastatic castration-resistant prostate cancer.

KEYWORDS:

PSMA; education; genitourinary; lutetium; radionuclide therapy; therapy

PMID:
28663195
DOI:
10.2967/jnumed.117.191023
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center